Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04347226
Recruitment Status : Terminated (Interim analysis indicated that futility boundary was reached.)
First Posted : April 15, 2020
Last Update Posted : November 30, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Matthew Dallos, Columbia University

Brief Summary:
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.

Condition or disease Intervention/treatment Phase
Solid Tumor Sars-CoV2 Hematological Malignancy Drug: BMS-986253 Phase 2

Detailed Description:
This is a single center, randomized, open-label, phase 2 trial to evaluate the time-to-improvement in the 7 point ordinal scale following treatment with anti-IL-8 therapy (BMS-986253) compared to standard of care in hospitalized patients with COVID-19 respiratory disease. Patients will be randomized 2:1 to receive either BMS-986253 or standard of care. Patients randomized to treatment with BMS-986253 will receive between 1-3 doses of therapy depending on their clinical status. Participants will be assessed daily while in the hospital and with then be followed for up to 1 year after discharge.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will receive either BMS-986253 2400mg intravenous (IV) at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if continued severe respiratory disease) or standard of care treatment.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
Actual Study Start Date : April 16, 2020
Actual Primary Completion Date : March 1, 2021
Actual Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BMS-986253
BMS-986253 2400mg IV
Drug: BMS-986253
BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).

No Intervention: Standard of Care treatment
Usual treatment of COVID-19 per study physician discretion

Primary Outcome Measures :
  1. Time to Improvement in the 7-point ordinal scale [ Time Frame: 1 year ]
    The time to improvement in the 7-point ordinal scale in patients treated with anti-IL-8 therapy compared to standard of care/controls. Measured from baseline to 2 point or greater improvement in 7-point ordinal scale.

Secondary Outcome Measures :
  1. Time to Death [ Time Frame: 1 year ]
    The time to death will be defined as the time from onset from symptoms until death from any cause. Patients who are alive or lost to follow-up at the cut-off date will be censored from this analysis.

  2. Time to Intubation [ Time Frame: 1 year ]
    The time to intubation will be defined as the time from symptom onset until time of intubation. Any patients already intubated at enrollment will be censored from this analysis.

  3. Proportion of patients requiring ICU admission [ Time Frame: 1 year ]
    The proportion of patients requiring intensive care unit (ICU) admission will be calculated as the number of patients requiring ICU admission over the course of their hospitalization over the number of evaluable patients.

  4. Percentage Rate of Mortality at 1 month [ Time Frame: 1 month ]
    Percentage of participants who have died 1 month from the time of start of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Male or female adult ≥ 18 years of age at time of enrollment.
  • Confirmed diagnosis of SARS-CoV-2 infection ≤ 14 days prior to registration.
  • Inpatient hospitalization (or documentation of a plan to admit to the hospital if the patient is in the emergency department)
  • Evidence of pneumonia by chest radiographs, chest CT OR chest auscultation (rales, crackles).
  • Severe respiratory disease (oxygen saturation ≤93% on room air and requiring supplemental oxygen) OR critical respiratory disease (requiring non-rebreather, non-mechanical/mechanical ventilation, high-flow nasal cannula, ICU admission).
  • Patients can continue their anti-cancer therapy at the discretion of the treating physician.
  • Adequate laboratory tests including:

    • absolute neutrophil count (ANC) >500 cells/mm3
    • Platelet count >20,000 cells/mm3
    • Serum total bilirubin <1.5 × upper limit of normal (ULN)
    • alanine aminotransferase (ALT) <5 × ULN
    • aspartate aminotransferase (AST) <5 × ULN
  • Age and Reproductive Status

    1. Males and females, aged at least 18 years old
    2. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study treatment.
    3. Women must not be breastfeeding.
    4. WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment plus for a total of 155 days post treatment completion. Local laws and regulations may require use of alternative and/or additional contraception methods.
    5. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements, but should still undergo pregnancy testing as described in this section.
    6. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception during study treatment with BMS-986253 for a total of 215 days post-treatment completion.
    7. Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements, and still must undergo pregnancy testing as described in this section.
  • Willingness to provide written informed consent and HIPAA authorization for the release of personal health information, and the ability to comply with the study requirements (note: HIPAA authorization will be included in the informed consent). In cases of partial impairment, impairment that fluctuates over time, or complete impairment due to dementia, stroke, traumatic brain injury, developmental disorders (including mentally disabled persons), serious mental illness, delirium, medical sedation, or intubation, a subject may be enrolled if the subject's legally authorized representative consents on the subject's behalf.

Exclusion Criteria

  • Treatment with anti-IL-6, anti-IL-6R antagonists or Janus kinase inhibitor (JAKi) within 48 hours of first dose of study treatment.
  • No other investigational therapies with the intent to treat the patient's COVID-19 can be administered while the patient is enrolled in the study.

    o Exception is remdesivir, hydroxychloroquine or other treatments being used as compassionate use for COVID-19.

  • Expected non-COVID-related survival of < 2 months.
  • Ongoing systemic immunosuppressive therapy ≤ 14 days prior to study treatment administration (except for adrenal replacement steroid doses ≤ 10mg daily prednisone equivalent in the absence of active autoimmune disease or a short course of steroids (<5 days) up to 7 days prior to initiating study treatment).
  • Receipt of non-oncology vaccines containing live virus for prevention of infectious diseases within 4 weeks prior to first dose of study treatment
  • History of severe hypersensitivity reaction to any monoclonal antibody (mAb)
  • Multi-organ failure requiring vasopressors or continuous veno-venous hemofiltration (CVVH) or extracorporeal membrane oxygenation.
  • No active systemic bacterial or fungal infection o Patients with a history of positive bacterial or fungal cultures but on enrollment do not have suspected or known active systemic bacterial or fungal infections are permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04347226

Layout table for location information
United States, New York
Columbia University Irving Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Matthew Dallos
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Matthew Dallos, MD Columbia University
Layout table for additonal information
Responsible Party: Matthew Dallos, Assistant Professor of Medicine at the Columbia University Medical Center, Columbia University Identifier: NCT04347226    
Other Study ID Numbers: AAAS9881
First Posted: April 15, 2020    Key Record Dates
Last Update Posted: November 30, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Matthew Dallos, Columbia University:
corona virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Neoplasms by Site
Hematologic Diseases